search
Back to results

Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
Belgium
Study Type
Interventional
Intervention
exenatide (Byetta)
Sponsored by
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring T2DM, exenatide, HbA1c, weight, waist circumference, insulin sensitivity, beta-cell function

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • type 2 diabetes subjects
  • 40 to 80 years
  • body mass index (BMI) between 25 and 40 kg/m²
  • baseline glycated haemoglobin (HbA1c) > 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin

Exclusion Criteria:

  • previous or current use of glitazone
  • previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine
  • previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors

Sites / Locations

  • Cliniques universitaires St-Luc

Outcomes

Primary Outcome Measures

Improvement in HbA1c

Secondary Outcome Measures

Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity

Full Information

First Posted
July 27, 2009
Last Updated
July 30, 2009
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
search

1. Study Identification

Unique Protocol Identification Number
NCT00948168
Brief Title
Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes
Official Title
6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients
Study Type
Interventional

2. Study Status

Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
July 2009 (Actual)
Study Completion Date
July 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug introduced to treat diabetes before addition of insulin to current therapy, over 6 months is associated with improvement in beta-cell function, insulin sensitivity following 24-hours discontinuation of the drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
T2DM, exenatide, HbA1c, weight, waist circumference, insulin sensitivity, beta-cell function

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
exenatide (Byetta)
Intervention Description
all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
Primary Outcome Measure Information:
Title
Improvement in HbA1c
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: type 2 diabetes subjects 40 to 80 years body mass index (BMI) between 25 and 40 kg/m² baseline glycated haemoglobin (HbA1c) > 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin Exclusion Criteria: previous or current use of glitazone previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors
Facility Information:
Facility Name
Cliniques universitaires St-Luc
City
Brussels
State/Province
Brabant
ZIP/Postal Code
1200
Country
Belgium

12. IPD Sharing Statement

Learn more about this trial

Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

We'll reach out to this number within 24 hrs